Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)

Federman & Sherwood Investigates Salix Pharmaceuticals, Ltd. for Possible Violations of Federal Securities Laws

 

Oklahoma City, OK (January 30, 2015) – The law firm of Federman & Sherwood has launched an investigation into Salix Pharmaceuticals, Ltd. [NASDAQ: SLXP] (“Salix”) for possible violations of federal securities laws.

 

On January 28, 2015 the Company’s audit committee announced that the consolidated financial statements for the full year 2013 and the first three quarters of 2014 require correction of certain errors and they should no longer be relied upon.  The errors were primarily associated with the timing of recognition of certain revenue, revenue-reducing returns and discounts, and expenses, on previously reported net income or loss after income taxes of each of these periods. 

If you currently own securities in Salix Pharmaceuticals, Ltd. and purchased your shares prior to January 28, 2015, have information to assist in our investigation, or want to be considered as a plaintiff in future litigation, please click here to download and complete our Investor Certification.  Once completed, please email the Investor Certification form to rkh@federmanlaw.com, fax to (405) 239-2112 or send by regular mail to:  Federman & Sherwood, Attn:  Robin, 10205 North Pennsylvania Avenue, Oklahoma City, OK  73120.  If you have any questions regarding this investigation, please contact William B. Federman. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases.

Copyright © 2017 Federman & Sherwood. All Rights Reserved.